Figure 3. TAK-242 prevents LPS-induced inflammation and insulin resistance in human myotubes.

Human myotubes were either left untreated or treated with 100 ng/ml LPS for 12 h. Prior to LPS exposure, cells were pre-treated with 1 µM TAK-242 or vehicle control for 1h. JNK phosphorylation (A), insulin-stimulated IRS-1-tyr612 (E), Akt (F), and AS160 (G) phosphorylation were determined by Western blotting. MCP-1 (B) and IL-6 (C) mRNA expression was determined by real time PCR. Glucose transport (D) was determined by measuring ³H-2-DG uptake. The absolute basal glucose transport rates were 43.2±3.2, 46.4±4.1, 46.7±5.6 and 46.5±6.8 pmol/mg,min in cells without LPS, cells with LPS, TAK-242-pretreated cells without LPS, and TAK-242-pretreated cells with LPS, respectively. Results for glucose transport are expressed as the mean ± SEM of data obtained from 5 subjects. All the rest of the values are the mean ± SD of triplicate determinations. Similar experiments were repeated 4 times using cells isolated from different subjects, and representative results are shown. *P<0.05; #P<0.05 compared to basal.